SEARCH

SEARCH BY CITATION

References

  • Agnello D, Lankford CS, Bream J et al. (2003) Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 23: 147161.
  • Ajdary S, Alimohammadian MH, Eslami MB, Kemp K & Kharazmi A (2000) Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 68: 17601764.
  • Alexander J, Satoskar A & Russell D (1999) Leishmania species: models of intracellular parasitism. J Cell Sci 112: 29933002.
  • Alexander J, Carter KC, Al-Fasi N, Satoskar A & Brombacher F (2000) Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30: 29352943.
  • Almeida RP, Rocha P, Jesus AR, Costa J & Carvalho EM (1995) Evaluation of cellular immune responses in patients with different clinical forms of tegumentary leishmaniasis. Allergy J Immunol 14: 1119.
  • Alvar J, Canavate C, Gutierrez-solar B et al. (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10: 298319.
  • Anderson CF, Oukka M, Kuchroo VJ & Sacks D (2007) CD4+CD25Foxp3 Th1 cells are the source of IL-10–mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204: 285297.
  • Antonelli LR, Dutra WO, Almeida RP, Bacellar O & Gollob KJ (2004) Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation. Clin Exp Immunol 136: 341348.
  • Awasthi A, Mathur RK & Saha B (2004) Immune response to Leishmania infection. Indian J Med Res 119: 238258.
  • Babaloo Z, Kaye PM & Eslami MB (2001) Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans R Soc Trop Med Hyg 95: 8588.
  • Bacellar O, Barral-Netto M, Badaro R & Carvalho EM (1991) Gamma interferon production by lymphocytes from children infected with L. chagasi. Braz J Med Biol Res 24: 791795.
  • Bacellar O, Brodskyn C, Guerreiro J et al. (1996) Interleukin-12 restores interferon-γ production and cytotoxic responses in visceral leishmaniasis. J Infect Dis 173: 15151518.
  • Barral-Netto M, Barral A, Brownell CE et al. (1992) Transforming growth factor-β in leishmanial infection: a parasite escape mechanism. Science 257: 545548.
  • Barral-Netto M, Brodskyn C, Carvalho EM & Barral A (1998) Human_Leishmaniasis/cytokines.bahia.br. Braz J Med Biol Res 31: 149155.
  • Belkaid Y (2003) The role of CD4 (+) CD25 (+) regulatory T cells in Leishmania infection. Expert Opin Biol Ther 3: 875885.
  • Belkaid Y, Hoffmann KF, Mendez S et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 14971506.
  • Belkaid Y, Piccirillo CA, Mendez S, Shevach EM & Sacks DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502507.
  • Ben-Sasson SZ, Le Gros G, Conrad DH, Finkelman FD & Paul WE (1990) IL-4 production by T cells from naive donors. IL-2 is required for IL-4 production. J Immunol 145: 11271136.
  • Biedermann T, Zimmermann S, Himmelrich H et al. (2001) IL-4 instructs Th1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2: 10541060.
  • Bittencourt A & Barral-Netto M (1995) Leishmaniasis. Tropical Pathology (DoeerW, ed.), p. 597. Springer-Verlag, Berlin.
  • Bogdan C, Gessner A & Rollinghoff M (1993) Cytokines in leishmaniasis: a complex network of stimulatory and inhibitory interactions. Immunobiology 189: 356396.
  • Bogdan C, Gessner A, Solbach W & Rollinghoff M (1996) Invasion, control and persistence of Leishmania parasites. Curr Opin Immunol 8: 517525.
  • Bogdan C, Rollinghof M & Diefenbach A (2000) The role of nitric oxide in innate immunity. Immunol Rev 173: 1726.
  • Bottrel RL, Dutra WO, Martins FA et al. (2001) Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun 69: 32323239.
  • Bourreau E, Gardon J, Pradinaud R et al. (2003) Th2 responses predominate during the early phases of infection in patients with localized cutaneous leishmaniasis and precede the development of Th1 responses. Infect Immun 71: 22442246.
  • Caldas A, Favali C, Aquino D et al. (2005) Balance of IL-10 and interferon-γ plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5: 113.
  • Campos-Neto A (2002) Anti-leishmania vaccine. Leishmania, 4 (FarrelJP, ed.), p. 169. Kluwer Academic Publishers, Boston, MA.
  • Campos-Neto A (2005) What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? Braz J Med Biol Res 38: 979984.
  • Campos-Neto A, Soong L, Cordova JL et al. (1995) Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. J Exp Med 182: 14231433.
  • Campos-Neto A, Porrozzi R, Greeson K et al. (2001) Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69: 41034108.
  • Carrera L, Gazzinelli RT, Badolato R et al. (1996) Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 183: 515526.
  • Carvalho EM, Badaró R, Reed SG, Jones TC & Johnson WD (1985) Absence of gamma interferon and interleukin-2 production during active visceral leishmaniasis. J Clin Invest 76: 20662069.
  • Carvalho EM, Bacellar O, Barral A, Badaro R & Johnson WD Jr (1989) Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest 83: 860864.
  • Carvalho EM, Barral A, Pedral-Sampaio D et al. (1992) Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis 165: 535540.
  • Carvalho EM, Bacellar O, Brownell C, Régis T, Coffman RL & Reed SG (1994) Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 59495956.
  • Chatelain R, Mauze S & Coffman RL (1999) Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol 21: 211218.
  • Cillari E, Vitale G, Arcoleo F et al. (1995) In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 7: 740745.
  • Costa SR, D'Oliveira A Jr, Bacellar O & Carvalho EM (1999) T cell response of asymptomatic Leishmania chagasi infected subjects to recombinant leishmania antigens. Mem Inst Oswaldo Cruz 94: 367370.
  • D'Oliveira A Jr, Costa SR, Barbosa AB, Orge M de la G & Carvalho EM (1997) Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis. Mem Inst Oswaldo Cruz 92: 1520.
  • Follador I, Araujo C, Bacellar O et al. (2002) Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 34: E54E58.
  • Gaafar A, Kharazmi A, Ismail A et al. (1995) Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections. Clin Exp Immunol 100: 239245.
  • Gantt KR, Schultz-Cherry S, Rodriguez N et al. (2003) Activation of TGF-β by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol 170: 26132620.
  • Garg R & Dube A (2006) Animal models for vaccine studies for visceral Leishmaniasis. Int J Med Res 123: 439454.
  • Ghalib HW, Piuvezam MR, Skeiky YA et al. (1993) Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324329.
  • Ghalib HW, Whittle JA, Kubin M et al. (1995) IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 154: 46234629.
  • Gorak PM, Engwerda CR & Kaye PM (1998) Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 28: 687695.
  • Hailu A, Van Baarle D, Knol GJ, Berhe N, Miedema F & Kager PA (2005) T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 117: 182191.
  • Haldar JP, Ghose S, Saha KC & Ghose AC (1983) Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 42: 702707.
  • Handman E (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14: 229243.
  • Heinzel FP, Rerko RM, Hatam F & Locksley RM (1993a) IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol 150: 39243931.
  • Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE & Gately MK (1993b) Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177: 15051509.
  • Jones DE, Merle Elloso M & Scott P (1998) Host susceptibility factors to cutaneous leishmaniasis. Front Bios 3: d1171d1180.
  • Julia V, Rassoulzadegan M & Glaichenhaus N (1996) Resistance to Leishmania major induced by tolerance to a single antigen. Science 274: 421423.
  • Karp CL, El-Safi SH, Wynn TA et al. (1993) In vivo cytokine profiles in patients with kalaazar. Marked elevation of both interleukin-10 and interferon-γ. J Clin Invest 91: 12651266.
  • Kemp K, Kemp M, Kharazmi A et al. (1999) Leishmania-specific T cells expressing interferon-gamma (IFN-γ) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 16: 500504.
  • Khalil EA, Ayed NB, Musa AM et al. (2005) Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clin Exp Immunol 140: 349353.
  • Kolde G, Luger T, Sorg C & Sunderkötter C (1996) Successful treatment of cutaneous leishmaniasis using interferon-γ. Dermatology 192: 5660.
  • Konecny P, Stagg AJ, Jebbari H, English N, Davidson RN & Knight SC (1999) Murine dendritic cells internalize Leishmania major promastigotes, produce IL-12p40 and stimulate primary T cell proliferation in vitro. Eur J Immunol 29: 18031811.
  • Kopf M, Brombacher F, Kohler G et al. (1996) IL-4-deficient BALB/c mice resist infection with Leishmania major. J Exp Med 184: 11271136.
  • Lainson R & Shaw JJ (1987) Evolution, classification and geographical distribution. The Leishmaniasis in Biology and Medicine, Vol. 1 (PetersW. & Killick-KendrickR., eds), pp. 1120. Academic Press, Orlando, FL.
  • Louzir H, Melby PC, Ben Salah A et al. (1998) Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J Infect Dis 177: 16871695.
  • Marovich MA, McDowell MA, Thomas EK & Nutman TB (2000) IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process. J Immunol 164: 58585865.
  • Martins GA, Hutchins AS & Reiner SL (2005) Transcriptional activators of helper T cell fate are required for establishment but not maintenance of signature cytokine expression. J Immunol 175: 59815995.
  • Mattner F, Magram J, Ferrante J et al. (1996) Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 26: 15531559.
  • McMahon-Pratt D & Alexander J (2004) Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev 201: 206224.
  • Melby PC (2002) Recent developments in leishmaniasis. Curr Opin Infect Dis 15: 485490.
  • Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD & Murray HW (1994) Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 62: 10581063.
  • Mougneau E, Altare F, Wakil AE et al. (1995) Glaichenhaus: expression cloning of a protective Leishmania antigen. Science 268: 563566.
  • Noben-Trauth N, Kropf P & Muller I (1996) Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 271: 987990.
  • Noben-Trauth N, Lira R, Nagase H, Paul WE & Sacks DL (2003) The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 170: 51525158.
  • Padigel UM, Alexander J & Farrell JP (2003) The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J Immunol 171: 37053710.
  • Pollock KG, McNeil KS, Mottram JC et al. (2003) The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses. J Immunol 170: 17461753.
  • Quinones M, Ahuja SK, Melby PC, Pate L, Reddick RL & Ahuja SS (2000) Preformed membrane associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite. J Exp Med 192: 507516.
  • Reed SG & Scott P (1993) T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 5: 524531.
  • Reed SG, Brownell CE, Russo DM, Silva JS, Grabstein KH & Morrissey PJ (1994) IL-10 mediates susceptibility to Trypanosomacruzi infection. J Immunol 153: 31353140.
  • Reed SG, Coler RN & Campos-Neto A (2003) Development of a leishmaniasis vaccine: the importance of Mpl. Expert Review of Vaccines 2: 239252.
  • Reiner SL & Locksley RM (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13: 151177.
  • Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O & Carvalho EM (1998) Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 31: 143148.
  • Rogers KA, DeKrey GK, Mbow ML, Gillespie RD, Brodskyn CI & Titus RG (2002) Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett 209: 17.
  • Sacks D & Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845858.
  • Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S & Ali N (2006) Immune responses in kala-azar. Indian J Med Res 123: 245266.
  • Scott P (1998) Differentiation, regulation, and death of T helper cell subsets during infection with Leishmania major. Immunol Res 17: 229238.
  • Scott P (2003) Development and regulation of cell-mediated immunity in experimental leishmaniasis. Immunol Res 27: 489498.
  • Scott P, Caspar P & Sher A (1990) Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol 144: 10751079.
  • Skeiky YA, Coler RN, Brannon M et al. (2002) Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in Mpl adjuvant. Vaccine 20: 32923303.
  • Snijders A, Kalinski P, Hilkens CM & Kapsenberg ML (1998) High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10: 15931598.
  • Suffia I, Reckling SK, Salay G & Belkaid Y (2005) A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J Immunol 174: 54445455.
  • Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS & Belkaid Y (2006) Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 203: 777788.
  • Sypek JP, Chung CL, Mayor SE et al. (1993) Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 177: 17971802.
  • Trinchieri G (2001) Regulatory role of T cells producing both interferon-γ and interleukin-10 in persistent infection. J Exp Med 194: F53F57.
  • Trinchieri G (2007) Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 204: 239243.
  • Uzonna JE, Spath GF, Beverley SM & Scott P (2004) Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 172: 37933797.
  • Von Stebut E & Udey MC (2004) Requirements for Th1-dependent immunity against infection with Leishmania major. Microbes Infect 6: 11021109.
  • Von Stebut E, Belkaid Y, Jakob T, Sacks DL & Udey MC (1998) Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med 188: 15471552.
  • Wang ZE, Reiner SL, Zheng S, Dalton DK & Locksley RM (1994) CD4+ effector cells default to the Th2 pathway in interferon-γ deficient mice infected with Leishmania major. J Exp Med 179: 13671371.
  • Webb JR, Kaufmann D, Campos-Neto A & Reed SG (1996) Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 157: 50345041.
  • WHO (1998) WHO information, by topic or disease. http://www.who.int/inf-fs/en/fact116.htm/
  • Wilhelm P, Ritter U, Labbow S, Donhauser N, Rollinghof M, Bogdan C & Korner H (2001) Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J Immunol 166: 40124019.
  • Wilson ME, Jeronimo SM & Pearson RD (2005) Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38: 147160.
  • Xu D, Liu H, Komai-Koma M et al. (2003) CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol 170: 394399.